Brief Communication: Successful Treatment of Pure Red-Cell Aplasia with an Anti–Interleukin-2 Receptor Antibody (Daclizumab)

  1. Elaine M. Sloand, MD;
  2. Phillip Scheinberg, MD;
  3. Jaroslaw Maciejewski, MD; and
  4. Neal S. Young, MD
  1. From National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
    1. Figure. Fifteen patients with pure red-cell aplasia were treated with daclizumab, 1 mg/kg of body weight, as described in the Methods section. Reticulocyte count, hemoglobin level, and transfusion history are seen for each patient. To convert hemoglobin values from g/dL to g/L, multiply value by 10.
      View larger version:
      Figure. Fifteen patients with pure red-cell aplasia were treated with daclizumab, 1 mg/kg of body weight, as described in the Methods section. Reticulocyte count, hemoglobin level, and transfusion history are seen for each patient. To convert hemoglobin values from g/dL to g/L, multiply value by 10. Clinical course of 6 responding patients after daclizumab treatment.
    « Previous | Next Article »Table of Contents

    This Article

    1. Ann Intern Med February 7, 2006 vol. 144 no. 3 181-185
    1. AbstractFREE
    2. » Figures
    3. Full Text
    4. Full Text (PDF)

    Rapid Responses

    1. Submit a response
    2. No responses published

    Current Issue

    1. November 17, 2009, 151 (10)
    1. Alert me to current issues